Trials / Terminated
TerminatedNCT02179359
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Conditions
- Sickle Cell Disease
- Transfusion Dependent Alpha- or Beta- Thalassemia
- Diamond Blackfan Anemia
- Paroxysmal Nocturnal Hemoglobinuria
- Glanzmann Thrombasthenia
- Severe Congenital Neutropenia
- Shwachman-Diamond Syndrome
- Non-Malignant Hematologic Disorders
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reduced Toxicity Ablative Regimen | * Anti-thymocyte Globulin (ATG) * Fludarabine * Busulfan * Stem Cell Infusion Day 0 |
| DRUG | Reduced Intensity Preparative Regimen | * Alemtuzumab * Cyclophosphamide * Fludarabine * Total Body Irradiation (TBI) * Stem Cell Infusion Day 0 |
| DRUG | Myeloablative Preparative Regimen | * Alemtuzumab * Cyclophosphamide * Busulfan * Stem Cell Infusion Day 0 |
Timeline
- Start date
- 2014-09-02
- Primary completion
- 2024-11-21
- Completion
- 2024-11-21
- First posted
- 2014-07-01
- Last updated
- 2025-03-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02179359. Inclusion in this directory is not an endorsement.